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Our current focus on the eﬀects of Photodynamic Therapy (PDT) using silicon phthalocyanine Pc 4 photosensitizer on malignant
T lymphocytes arose due to preclinical observations that Jurkat cells, common surrogate for human T cell lymphoma, were
more sensitive to Pc 4-PDT-induced killing than epidermoid carcinoma A431 cells. Mycosis fungoides (MF) as well as Sezary
syndrome (SS) are variants of cutaneous T-cell lymphoma (CTCL) in which malignant T-cells invade the epidermis. In this study,
we investigated the cytotoxicity of Pc 4-PDT in peripheral blood cells obtained from patients with SS and in skin biopsies of
patients with MF. Our data suggest that Pc 4-PDT preferentially induces apoptosis of CD4+CD7− malignant T-lymphocytes in the
blood relative to CD11b+ monocytes and nonmalignant T-cells. In vivo Pc 4-PDT of MF skin also photodamages the antiapoptotic
protein Bcl-2.
1.Introduction
Photodynamic therapy (PDT) involves exposure of tumors
to a photosensitizing drug followed by irradiation with
light of an appropriate wavelength. PDT is eﬀective in the
treatment of cancers of diﬀerent organ systems including the
lungs, bladder, gastrointestinal tract, and skin. Cutaneous
neoplasms serve as ideal targets of PDT due to their
accessibility. Moreover, PDT of skin lesions provides the
opportunity to utilize optical instrumentation that could
monitor treatment parameters in real time [1] and poten-
tially capture mechanistic events occurring in the tumor in
vivo. In dermatology, PDT is approved for the treatment
of actinic keratoses but has been used oﬀ-label to treat
basal cell carcinoma, Bowen’s disease, and mycosis fungoides
[2]. The interaction of photosensitizer, light, and oxygen
results in oxidative stress that destroys the pathologic cells.
Due to the prolonged skin photosensitivity that systemic
photosensitizerssuchasPhotofrincouldcause,topicalagents
such as 5-aminolevulinic acid (ALA) and its derivatives
are preferred [3] in the PDT of cutaneous disease. ALA-
PDT, however, has unwanted side eﬀects such as pain,
irritation, and edema during and after treatment. Due to
its limited penetration into the skin, ALA is eﬀective in
treating lesions only 2-3mm deep [4]. ALA also requires an
incubation period between application and light exposure to
allow its metabolic conversion into the active photosensitizer
protoporphyrin IX (PpIX). Thus, development of other
topical PDT drugs with better safety and eﬃcacy proﬁles is
warranted.2 Advances in Hematology
The silicon phthalocyanine Pc 4 [HOSiPcOSi(CH3)2
(CH2)3N(CH3)2] is a second generation photosensitizer that
more eﬃciently absorbs red light at a longer wavelength (λ =
675nm; ε = 2 × 105) than PpIX (peak furthest to the red
λ = 630nm; ε ≈ 5 × 103)[ 5]. Pc 4 binds to mitochondria,
endoplasmic reticulum (ER), Golgi, and perinuclear mem-
branes [6]. Photo-irradiating cells with 675nm light after
treatment with Pc 4 generates reactive oxygen species (ROS),
for example, singlet oxygen, which leads to instantaneous
modiﬁcations of biological molecules, such as lipids and
proteins [7–9]. Within minutes to hours, this can lead to
necrosis as well as the activation of programmed cell death
or apoptosis [10]. Secondary local and systemic events such
as inﬂammation and/or antitumor immune responses occur
within days or months, depending upon cell type or tumor
treated, as well as on the photosensitizer and light regimen
used [11].
PDT-dependent cellular protein modiﬁcations may
include protein oxidation, cross-linking, and degradation
[9, 12–14]. Because these phenomena occur in an early
stage of PDT, they may serve as a useful marker for early
apoptotic events. As an important regulator of apoptosis, the
mitochondrial membrane protein Bcl-2 functions to block
apoptosis by inhibiting the release of cytochrome c.P c4 -
PDT, as well as PDT with a variety of photosensitizers,
photodamages Bcl-2 with a dose-response that correlates
with cell killing [12, 15]. Bcl-2 photodamage is characterized
on western blots as the immediate nonenzymatic loss of
the native protein and the formation of slower migrating
complexes of Bcl-2 with neighboring proteins and lipids
[16]. Another early marker of apoptosis is the Apo 2.7
antigen, a 38kDa protein that is detected on the membrane
ofmitochondriawhencellsareintheearlystageofapoptosis,
suggesting that this protein may be involved in an early event
of the molecular cascade [17]. Furthermore, the Apo 2.7
antigen is expressed in apoptotic cells but not in normal cells
or cells that undergo death by nonapoptotic mechanisms,
such as necrosis.
Our previous ﬁndings indicated that Jurkat cells were
more sensitive to Pc 4-PDT-induced killing than epidermoid
carcinoma A431 cells, while uptake of Pc 4 by both cell
populations was shown to be similar in low to moderate
doses (0.1nM to 100nM) [18], suggesting that Pc 4-
PDT might be more eﬀective in treating lymphomas than
epithelial cancers. In both epidermoid and Jurkat cells, PDT
with Pc 4 promotes the mitochondrion-mediated pathway
of apoptosis, leading to eventual cell death [7]. The greater
sensitivity of Bcl-2 to photodamage in Jurkat cells correlates
with the greater response seen in those cells, indicating a
role for Bcl-2 damage in the response in both cell types.
These results suggest that Pc 4-PDT may oﬀer a therapeutic
advantage in targeting malignant T-cells of cutaneous T-cell
lymphoma (CTCL) [18].
Mycosis fungoides (MF) is the most common type of
CTCL accounting for almost 70% of all primary cutaneous
lymphomas [19]. Sezary syndrome (SS) is the leukemic form
of CTCL, involving the skin, lymph nodes, and peripheral
blood. Patients with SS can have detectable levels of the





































∗ P ≤ .05
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Percentage of apoptosis in normal CD4+CD7+,
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Figure 1: Pc 4-PDT dose response for the induction of apoptosis in
CD4+CD7− malignant lymphocytes, CD4+CD7+ normal lympho-
cytes, and CD11b
+ monocytes of patients with Sezary syndrome.
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-histopaque centrifugation and then treated with Pc 4 at 0–
100nM followed by photoirradiation (200mJ/cm2).
immunophenotype of these cells is often characterized by
the expression of CD4 and absence of CD7 [20, 21]. In
this study, we investigated the susceptibility of malignant T-
lymphocytes that characterizes SS to the phototoxic eﬀects
of Pc 4-PDT ex vivo, and the eﬀe c to fP c4 - P D Tin vivo to
damage the antiapoptotic protein Bcl-2 in the skin lesions of
MF.
Peripheral blood mononuclear cells (PBMCs) were
obtained from patients with SS and treated with Pc 4-PDT.
Apoptosis was detected (by positive staining with APO 2.7+)
in the PBMC preparation, and levels of apoptosis observed
in malignant CD4+CD7+ Tc e l l sversus normal bystander T
cells and non-T cells were compared by ﬂow cytometry. Pc
4-PDT treated skin biopsy specimens obtained from patients
with MF were evaluated forchanges and/or the level of Bcl-2,
as an indication of apoptosis-related photodamage.
2.MaterialsandMethods
A l lp r o c e d u r e si n v o l v i n gh u m a ns u b j e c t sw e r ea p p r o v e db y
the Institutional Review Boards of Case Western Reserve
University, University Hospitals Case Medical Center and the
Veterans Aﬀairs Medical Center.
2.1. PBMC Isolation and Preparation. PBMCs were isolated
by Ficoll-Histopaque centrifugation from 60ml of whole
blood as described previously [22]. Samples were taken from
three patients (age 67 to 82, 2M: 1F) with a diagnosis of SS
conﬁrmedbythepresenceofmorethan10%CD4+CD7− cir-















































































































































































Figure 2: Representative ﬂow cytometric histograms of the induced apoptosis of CD4+CD7− lymphocytes treated with Pc 4-PDT. Total
blood was obtained from patients diagnosed with Sezary syndrome. The histograms shown were taken from a single patient with SS. PBMCs
were isolated, treated with Pc 4, and stained as mentioned previously in the Methods section. Lymphocytes were identiﬁed by their high
CD4 expression (y-axis) and forward scatter (x-axis) as shown in yellow (region R2) in (a). CD4+CD7− lymphocytes are shown in region
R7 in (c). Levels of apoptosis in this population were analyzed in all three Pc 4-PDT doses. The data shown in (e), (f), and (g) exhibit a dose-
dependent response in apoptosis induction among the three Pc 4-PDT concentrations. Levels of apoptosis in all three doses are signiﬁcantly
higher than in the untreated group shown in (h). Untreated cells were incubated with Pc 4 overnight but were not photo irradiated.
Cell viability was determined by trypan blue exclusion and
was quantiﬁed using a hemocytometer.
2.2. Pc 4-PDT of PBMCs. PBMCs from each patient were
cultured at 106 per ml of complete medium (RPMI 1640
supplemented with 10% fetal bovine serum, 1% Pen Strep
solution, and 1% L-glutamine) in 60mm cell culture plates.
Pc 4 (provided by Dr. Malcolm E. Kenney, Chemistry
Department, Case Western ReserveUniversity) wasdissolved
in N,N-dimethylformamide (DMF) to prepare a 0.5mM
stock solution. It was further diluted in complete medium to








































































































































Figure 3: Representative ﬂow cytometric histograms of the induced apoptosis of CD4+CD7+ lymphocytes treated with Pc 4-PDT. Total
blood was obtained from patients diagnosed with Sezary syndrome. The histograms shown were taken from a single patient with SS. PBMCs
were isolated, treated with Pc 4, and stained as mentioned previously in the Methods section. Lymphocytes were identiﬁed by their high CD4
expression (y-axis) and forward scatter (x-axis) as described previously. CD4+CD7+ lymphocytes were further identiﬁed in region R24 in
(a). Levels of apoptosis induced by all three doses in this population were then analyzed. As shown in (b), (c), and (d), these levels remained
relatively similar and P-values were largely insigniﬁcant from group to group. Apoptosis induction in the untreated group is shown in (e).
medium was then added to the PBMCs, which were
incubated at 37◦C for one hour. The PBMC cultures were
irradiated using a LED array (λmax ≈ 670–675nm) at a
ﬂuence of 200mJ/cm2 as previously described [8]. After
irradiation, the cells were incubated from 16 to 18 hours at
37◦Ct oa l l o ws u ﬃcient time for apoptosis induction.
2.3. Flow Cytometry Analysis. Following Pc 4-PDT and
overnight incubation as described above, PBMCs were
characterized and phenotyped by ﬂow cytometry. The
total PBMCs were gated into three distinct populations
(CD4+CD7+ T-lymphocytes, CD4+CD7− malignant lym-
phocytes, and CD11b+ monocytes). FACS analysis was
performed on an LSR II four-laser ﬂow cytometer (Becton
Dickson, Franklin Lakes, NJ). Antibodies used to identify the
cell surface antigens were mouse antihuman CD4 (identiﬁed
with PerCp), mouse antihuman CD7 (identiﬁed with FITC)
(BD Pharmingen, San Jose, CA), and mouse antihuman
CD11b+ (identiﬁed with APC) (Becton Dickson, Franklin
Lakes, NJ). Levels of apoptosis induced by Pc 4-PDT
in each population were characterized by permeabilizing
the cells with digitonin and staining them with APO 2.7
PE-conjugated antibody (Immunotech/Beckman Coulter,
Marseille, France).
2.4. Skin Biopsy Acquisition. Biopsies that were previously
acquired from a Phase I clinical trial, consisting of three- to
six-mm punch specimens of early stage MF, were utilized for
this analysis. In the Phase 1 trial, Pc 4-PDT was performed
on selected MF lesions, whereas other MF lesions in the
same patient served as untreated controls. Biopsies of both
the untreated and treated lesions were obtained 24 hours
after Pc 4-PDT and stored for analysis. Complete results of
this clinical trial will be published elsewhere (manuscript
under review). For this particular experiment, frozen tissue
samples were chosen from three patients whose lesions
partially responded to Pc 4-PDT, and three who were clinical
nonresponders.
2.5. Western Blot. Each tissue sample was homogenized
using a Polytron blender, and 30–60μg of protein extracted
from each sample was subjected to SDS-PAGE on Invitrogen
NuPAGE Bis-Tris 4–12% Gels. The proteins were transferred
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Figure 4: Representative ﬂow cytometric histograms of the induced apoptosis of CD11b+monocytes treated with Pc 4-PDT. Total blood
was obtained from patients diagnosed with Sezary syndrome. The histograms shown were taken from a single patient with SS. PBMCs were
isolated, treated with Pc 4, and stained as mentioned previously in the Methods section. Monocytes were identiﬁed by their high CD11b+
expression (y-axis) and forward scatter (x-axis) as shown in yellow (Region R18) in (a). Levels of apoptosis in all three Pc 4-PDT doses were
then further analyzed from this population. As shown in (c), (d), and (e), levels of apoptosis were similar in the three treatment groups.
Apoptosis induction in the untreated group is shown in (f).
to conﬁrm the transfer, and incubated in blocking buﬀer
(5% milk-TBST) for 48 hours at 4◦C. Immunoblot analysis
was conducted with puriﬁed hamster antihuman Bcl-2
monoclonalantibody(BDPharmingen,SanJose,CA;1:1000
dilution) followed by horseradish peroxidase-conjugated
mouse antihamster secondary antibody (BD Pharmingen,
San Jose, CA; 1:5000 dilution), and then developed using the
Super Signal West Pico Kit (Super Signal West Pico, Pierce,
Rockford, IL, USA). As a loading control, actin was detected
using antiactin (Novus Biologicals, LLC, Littleton, CO).
3. Results
PBMCs from three patients with Sezary syndrome were
exposed to Pc 4-PDT in vitro, and three subpopulations were
evaluated for apoptosis 24h later by staining with APO 2.7
andﬂowcytometry(Figure1).Themoststrikingobservation
was a marked PDT dose-dependent increase in apoptosis in
the malignant CD4+CD7− Tl y m p h o c y t e s .T h ea v e r a g el e v e l
of apoptosis in the malignant cells increased signiﬁcantly
from 25% of the untreated cells to 51.9%, 70.4%, and 83.6%,
following irradiation of cells given 20, 70, and 100nM Pc
4, respectively. This result is in sharp contrast to the levels
of apoptosis exhibited in CD4+CD7+ T-lymphocytes and
CD11b+ monocytes. At all PDT doses, there was signiﬁcantly
greater APO 2.7 positive cells among CD4+CD7− malignant
T-cells compared to either the nonmalignant or monocytic
cell populations, whose levels of apoptosis ranged from
17.3% to 30.2% and from 26.4% to 37.2%, respectively. In
themonocyticcell(CD11b+)population,thelevelofapopto-
sis increased slightly with each increment in Pc 4-PDT dose,
but remained statistically insigniﬁcant in comparison to the
levels in untreated monocytes. In addition, the degree of
apoptoticmonocyticcelldeathwasnotsigniﬁcantlydiﬀerent
amongst the Pc 4 doses that were examined. Although a
statistical diﬀerence was found between the monocytic cells
treated with the 20nM and 100nM doses (P ≤ .003), the
levels of apoptosis are far below those induced by Pc 4-PDT
in the malignant T-cell population. A similar phenomenon
was observed in the benign (CD4+CD7+) T-cell population,
even though a statistical diﬀerence was observed between
the cells treated with 70nM and 100nM (P ≤ .01). Levels
of apoptosis induced in this population were again far
below those in the malignant clones for each dose. This
distinct feature seen in both benign cell populations suggests
an apparent speciﬁcity of Pc 4 in the killing of targeted
cancerous cells. Representative ﬂow cytometric histograms
for CD4+CD7− T-cells, CD4+CD7+ T-cells, and CD11b+
monocytesfromonepatientwithadiagnosisofSSareshown
in Figures 2, 3,a n d4,r e s p e c t i v e l y .6 Advances in Hematology
Expression of Bcl-2 after Pc 4-PDT
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Figure 5: Representative Western blots of Bcl-2 expression after in vivo treatment with Pc 4-PDT. Skin biopsies of MF lesions were obtained
from patients diagnosed with MF. This Western blot compares Bcl-2 expression in a single representative clinical responder to that of a single
representative clinical nonresponder. The top panels in both (a) and (c) show the 26 KDal Bcl-2. (b) and (d) show bands corresponding
to actin as loading control. For both the responder (a and b) and nonresponder blots (c and d), Lane 1 consists of Jurkat cells, a cell line
known to have endogenous expression of Bcl-2. Lane 2 consists of Wehi cells, a mouse cell line known to have minimal endogenous Bcl-
2 expression. Lanes 3 and 4 contain the extraction from the untreated and treated lesions, respectively. (a) The clinical responder patient
shows signiﬁcantly decreased Bcl-2 expression in treated lesions in comparison to Bcl-2 expression in untreated lesion. In Lane 2, there is
no corresponding band, as expected. (b) In the clinical nonresponder patient, again, there is Bcl-2 expression detected in Jurkat cells and
no expression in Wehi cells, as expected. However, in contrast to the clinical responder patient, the level of Bcl-2 expression in treated and
untreated lesions of the nonresponder is similar. These results are supported by the level of actin protein, which shows approximately similar
amounts of protein loaded.
As another indicator of PDT-induced photodamage
leading to apoptosis, skin biopsies from MF patients were
evaluated for the level of native Bcl-2 by western blot
analysis (Figure 5). There was a signiﬁcant decrease in Bcl-
2 levels in response to Pc 4-PDT, but only in biopsies of
thosepatientswhodemonstratedapartialresponseclinically.
A representative blot from one such patient is shown in
Figure 5(a). The level of Bcl-2 in the MF lesion of this patient
after Pc 4-PDT treatment is notably reduced in comparison
to the Bcl-2 level in the untreated lesion of the same patient.
In contrast, the levels of Bcl-2 expression in both treated
and untreated lesions are similar in the skin biopsy of the
nonresponder (Figure 5(c)).
4. Discussion
The ﬂow cytometry analysis and APO 2.7 staining of Pc 4-
PDT-treated PBMCs from patients with SS demonstrated
that Pc 4-PDT more eﬀectively induces apoptosis in Sezary
cells compared to other cell types. This mechanism of
preferential killing of malignant lymphocytes remains enig-
matic. One hypothesis is that the increased susceptibility
of malignant cells may be related to changes involving
the antiapoptotic protein Bcl-2, which has been found to
be overexpressed in MF and SS [23], although subsets of
patients lacking Bcl-2 have been reported [24]. This study
also found that the response to Pc 4-PDT occurs in a Pc
4 dose-dependent manner. However, the increased level of
apoptosis induced in CD4+CD7− T-cells by the 100nM dose
compared to the 70nM dose of Pc 4 was not statistically
signiﬁcant. It is possible that beyond the 70nM dose the
cells are already saturated with Pc 4 and so further increases
do not result in increased apoptosis. Further experiments
examining the eﬀect of the intermediate doses of Pc 4
between 20nM and 70nM, as well as between 70nM and
100nM to optimize dosing are ongoing.
The Western blot analyses of MF skin lesions treated
with Pc 4-PDT conﬁrmed that this treatment is capable
of reducing intracellular levels of Bcl-2 in malignant T-
lymphocytes in vivo, consistent with our previous in vitro
data [12]. The decrease in antiapoptotic Bcl-2 suggests that
Pc4-PDTenhancedapoptosis inthesecells,whichtranslated
to clinical improvement. Conversely, when there was no
change in Bcl-2 levels detected after Pc 4-PDT, no response
was observed clinically. These observations support previous
ﬁndings that photodamage to Bcl-2 is a critical component
in the mechanism of Pc 4-PDT-mediated cell killing. More
studies are being conducted using skin biopsies from T-
cell driven pathologies such as CTCL to further assess the
selectivity of cell killing after Pc 4-PDT.
In summary, this study has shown that photodynamic
therapy with Pc 4 can be delivered at a dose that induces
killing of malignant lymphocytes in the peripheral blood
and in tissue of patients with CTCL. Selective killing of
malignant CD4+CD7− T-cells over normal bystander cells
was observed in vitro, which suggests that Pc 4-PDT can
potentially be utilized as a target-speciﬁc anticancer therapy
for malignancies such as CTCL. Therapies aimed at arrestingAdvances in Hematology 7
neoplastic growth ideally should be able to eliminate aber-
rant cells while preserving the normal components of the
tissue or organ. In theory, such a target-speciﬁc modality
could result in clinical cure with limited adverse side eﬀects,
suchasimmunosuppression,severetissueinﬂammation,and
necrosis, which are commonly observed with other anti-
cancer treatments like chemotherapy and radiation.
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